Compugen (CGEN) Corporate presentation summary

Vision and platform

• Aims to transform patient lives by developing first-in-class therapeutics using a proprietary computational target discovery platform, Unigen™.

• Integrates multi-omics, deep learning, and predictive algorithms for rapid target validation and drug candidate development.

Pipeline and partnerships

• Focuses on novel immuno-oncology antibodies, with a rich pipeline and validating partnerships, including AstraZeneca and Gilead.

• Pipeline includes COM701 (anti-PVRIG), COM902 (anti-TIGIT), rilvegostomig (PD1/TIGIT bispecific), GS-0321 (anti-IL-18BP), and multiple early-stage assets.

• Eligible for over $1 billion in milestones plus royalties from partnerships.

Lead programs and clinical data

• COM701 demonstrated clinical benefit and durable responses in platinum-resistant ovarian cancer, with a favorable safety profile.

• COM701 adaptive platform trial in relapsed platinum-sensitive ovarian cancer to initiate in Q2 2025, with interim analysis projected for H2 2026.

• COM902 shows high affinity, favorable safety, and disease control in multiple tumor types; rilvegostomig, derived from COM902, is in broad Phase 3 development with AstraZeneca.

• GS-0321, a first-in-class anti-IL-18BP antibody, is advancing in a global Phase 1 trial for advanced solid tumors, with Gilead holding commercialization rights.